GSK: positive results for influenza vaccine

(CercleFinance.com) - GSK has announced positive results from a Phase II trial (NCT06431607) for its seasonal influenza mRNA vaccine program.


A candidate vaccine formulation demonstrated positive immune responses to strains A and B compared to standard care in younger and older adults

These results build on the previous Phase II trial and confirm that the mRNA platform elicits high overall antibody titers with an acceptable safety profile. With these results, GSK's mRNA seasonal influenza vaccine program will move into late-stage clinical development.

Tony Wood, Chief Scientific Officer of GSK, said that this is a significant step forward in our mRNA program, and these data support the move into late-stage development. Ultimately, our goal is to develop a first-in-class new vaccine to offer people better protection during the flu season.


Copyright (c) 2024 CercleFinance.com. All rights reserved.